What is Biopharma SHAKTI scheme?
Historical Background
Key Points
10 points- 1.
Provides financial support for research and development projects in the biopharmaceutical sector.
- 2.
Aims to create a conducive environment for biopharma innovation.
- 3.
Supports the development of new drugs and therapies.
- 4.
Promotes collaboration between industry, academia, and government.
- 5.
Encourages investment in biopharmaceutical manufacturing facilities.
- 6.
Visual Insights
Biopharma SHAKTI Scheme: Key Components and Objectives
Mind map illustrating the key components, objectives, and linkages of the Biopharma SHAKTI scheme.
Biopharma SHAKTI Scheme
- ●Objectives
- ●Key Components
- ●Beneficiaries
Source Topic
India's Health Budget 2026: Increased Allocations, Missed Targets, Mixed Outcomes
Social IssuesUPSC Relevance
Frequently Asked Questions
61. What is the Biopharma SHAKTI scheme and why is it important for UPSC GS Paper 3?
The Biopharma SHAKTI scheme is a proposed government initiative designed to strengthen the biopharmaceutical sector in India by promoting research, development, and innovation. It is important for UPSC GS Paper 3 because it relates to Economic Development, Government Schemes, and Science and Technology, all of which are key areas of the syllabus. Questions on healthcare policy and government initiatives in the biopharmaceutical industry are likely to be asked.
Exam Tip
Remember the key areas the scheme addresses: research, development, and innovation in the biopharmaceutical sector. Link it to broader economic and healthcare policy questions.
2. What are the key provisions that are expected to be included in the Biopharma SHAKTI scheme?
Based on the concept data, the key provisions of the Biopharma SHAKTI scheme are expected to include: * Financial support for research and development projects. * Creation of a conducive environment for biopharma innovation. * Support for the development of new drugs and therapies. * Promotion of collaboration between industry, academia, and government. * Encouragement of investment in biopharmaceutical manufacturing facilities.
